drugset
drugset / Trial / NCT02271412

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

NCT02271412 ↗

Phase 1 Completed 58 enrolled Luye Pharma Group Ltd.
RandomizedSingle-groupDouble-blindBasic science

Summary

Objectives * To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. * To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.

Timeline

Start
2014-10
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Toludesvenlafaxine Small molecule 40 mg Oral
Subject Toludesvenlafaxine Small molecule 80 mg Oral
Subject Toludesvenlafaxine Small molecule 120 mg Oral
Subject Toludesvenlafaxine Small molecule 160 mg Oral

Indications

major depressive disorder